|
| | | | | | | | | | | |
| Name | Indication | Approved | MOA | Economics | Administration | IP | | Price | 151 | |
| Humira (adalimumab) | RA, PSO, CD, UC, PsA, HS, Uveitis, AS | 12/31/2002 | TNF | 1 | Subcutaneous | 2024 | | Shares | 1768.480508 | Q322 |
| Botox (onabotulinumtoxinA) | Aesthetics, Cervical Dystonia | 12/9/1991 | Botulinim | 1 | Subcutaneous | Unclear | | MC | 267040.556708 | |
| Imbruvica (ibrutinib) | CLL, GvHD, WM | 11/13/2013 | BTK C481 | JNJ | Oral | 6/28/2027 | | Cash | 12114 | Q322 |
| Skyrizi (risankizumab) | Psoriasis, PsA, Crohn's | 4/23/2019 | IL-23 | BI | Subcutaneous | Biologic | | Debt | 69606 | Q322 |
| Venclexta (venetoclax) | CLL, AML | 4/11/2016 | BCL-2 | Roche | Oral | 2030-2033 | | EV | 324532.556708 | |
| Lupron Depot (leuprolide) | CRPC | 1/26/1989 | | 100%? Takeda? | IM | | | | | |
| Rinvoq (upadacitinib) | RA, axSpA | 3/16/2022 | JAK | 1 | Oral | 2030+ | | | | |
| Synthroid (levothyroxine) | Hypothyroidism | 7/24/2002 | | | Oral | | | | | |
| Creon | Pancreatic Insufficiency | | | | Oral | | | | | |
| Restasis (cyclosporine) | Dry Eye | | | | Eyedrop | | | | | |
| Duodopa (carbidopa/levodopa) | Parkinson's Disease | | | | | | | CEO: Richard Gonzalez | | |
| Orilissa (elagolix) | Uterine Fibroids | | | NBIX | Oral | | | CFO: Robert A. Michael | | |
| Qulipta (atogepant) | Migraine | | CGRP | 1 | Oral | | | | | |
| Viekira (paritaprevir, ombitasvir) | HCV | | | 1 | Oral | | | | | |
| Vuity (pilocarpine) | Presbyopia | | | | Eyedrop | | | | | |
| Juvederm, Volux XC | Jawline Aesthetics | | Dermal HA Filler | | | | | | | |
| Durysta (bimatoprost) | Glaucoma | | | | Eyedrop | | | | | |
| Vraylar (cariprazine) | Schizophrenia, Bipolar | | | | Oral | | | | | |
| | | Phase | | | | | | | | |
| ABBV-951 (foscarbidopa/foslevodopa) | Parkinson's Disease | NDA | | 1 | | | | | | |
| ABBV-154 | RA, PMR, Crohn's | II | ASC | 1 | | | | | | |
| epcoritamab | | | CD3xCD20 | GMAB | | | | | | |
| telisotuzumab vedotin | NSCLC | | | | | | | | | |
| BoNTE (AGN-151586) | Glabellar Lines | | | | | | | | | |
| ABBV-157 | Psoriasis | II | RORgammaT | 1 | | | | | | |
| ABBV-105 | SLE | II | BTK | 1 | | | | | | |
| elsubrutinib ABBV-599 (-105+Rinvoq) | SLE | II | BTK+JAK | 1 | | | | | | |
| ABBV-668 | Autoimmune | I | RIPK1 | 1 | | | | | | |
| ALPN-101 | SLE | II | CD28/ICOS | ALPN | | | | | | |
| lutikizumab | HS | II | IL-1a/1b | 1 | | | | | | |
| ABBV-0805 | Parkinson's Disease | I | alpha-synuclein | 1 | | | | | | |
| ABT-333 | HCV | | | | | | | | | |
| ABT-414 | GBM | | | | | | | | | |
| DJS-002 | IPF | I | LPAR1 mab | 1 | | | | | | |
| ABT-888 (veliparib) | Ovarian Cancer | II | PARP | 1 | | | | | | |
| ABT-981 | OA | | | | | | | | | |
| ABT-700 | Cancer | | | | | | | | | |
| ABT-767 | | | | | | | | | | |
| | | | | | | | | | | |
| | | | 10/28/22: Q322 results | | Discontinued | | | | | |
| | | | | | ABT-354 for Alzheimer's. 5HT6? | | | | | |